公开(公告)号：US11896635B2

公开(公告)日：2024-02-13

申请号：US16758019

申请日：2018-11-08

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro Kosai ,  Nobuhiro Ijichi

IPC: C12N7/00 ,  A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

CPC classification number: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.

公开(公告)号：US20240148807A1

公开(公告)日：2024-05-09

申请号：US18406002

申请日：2024-01-05

Applicant: Kagoshima University

Inventor： Ken-ichiro KOSAI ,  Nobuhiro Ijichi

IPC: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

CPC classification number: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.